eXoZymes (NASDAQ:EXOZ) Stock: Insider Damien Alan Perriman Sells 3,729 Shares

eXoZymes Inc. (NASDAQ:EXOZ) insider Damien Alan Perriman sold 3,729 shares of the stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $5.21, for a total transaction of $19,428.09. Following the sale, the insider owned 28,692 shares in the company, valued at approximately $149,485.32. This trade represents a 11.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

eXoZymes Stock Performance

NASDAQ EXOZ traded down $0.04 during trading hours on Monday, reaching $3.96. The company’s stock had a trading volume of 16,572 shares, compared to its average volume of 6,871. The company has a current ratio of 3.81, a quick ratio of 3.81 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $5.96 and a 200 day simple moving average of $7.40. eXoZymes Inc. has a 52 week low of $3.70 and a 52 week high of $18.40. The stock has a market cap of $36.83 million, a PE ratio of -3.33 and a beta of 3.19.

eXoZymes (NASDAQ:EXOZ) last issued its earnings results on Thursday, August 13th. The company reported ($0.33) EPS for the quarter. Equities research analysts predict that eXoZymes Inc. will post -1.19 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently issued reports on EXOZ. Weiss Ratings restated a “sell (e+)” rating on shares of eXoZymes in a research report on Wednesday, August 26th. Zacks Research upgraded eXoZymes to a “hold” rating in a research note on Friday, October 2nd. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, eXoZymes currently has an average rating of “Reduce”.

Institutional Trading of eXoZymes

A hedge fund recently bought a new position in eXoZymes stock. BlackRock Inc. bought a new stake in shares of eXoZymes Inc. (NASDAQ:EXOZ) in the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 9,610 shares of the company’s stock, valued at approximately $81,000. BlackRock Inc. owned 0.10% of eXoZymes as of its most recent SEC filing.

About eXoZymes

eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.